DrugPatentWatch Database Preview

Details for Patent: 7,727,984

« Back to Dashboard

Which drugs does patent 7,727,984 protect, and when does it expire?

Patent 7,727,984 protects STIOLTO RESPIMAT and STRIVERDI RESPIMAT and is included in two NDAs.

This patent has forty-three patent family members in thirty-four countries.

Summary for Patent: 7,727,984

Title:	Medicaments for the treatment of chronic obstructive pulmonary disease
Abstract:	A pharmaceutical composition comprising a compound of formula 1 ##STR00001## wherein: n is 1 or 2; R.sup.1 is hydrogen, C.sub.1-C.sub.4-alkyl, halogen, OH, or --O--C.sub.1-C.sub.4-alkyl; R.sup.2 is hydrogen, C.sub.1-C.sub.4-alkyl, halogen, OH, or --O--C.sub.1-C.sub.4-alkyl; R.sup.3 is hydrogen, C.sub.1-C.sub.4-alkyl, OH, halogen, --O--C.sub.1-C.sub.4-alkyl, --O--C.sub.1-C.sub.4-alkylene-COOH, or --O--C.sub.1-C.sub.4-alkylene-CO--O--C.sub.1-C.sub.4-alkyl, or an acid addition salt thereof with a pharmacologically acceptable acid, or a solvate or hydrate thereof; and a pharmaceutically acceptable excipient or carrier, and methods for using the pharmaceutical formulation in the treatment of chronic obstructive pulmonary disease (COPD).
Inventor(s):	Konetzki; Ingo (Warthausen, DE), Schromm; Kurt (Ingelheim am Rhein, DE), Schollenberger; Hermann (Ingelheim am Rhein, DE), Pestel; Sabine (Biberach, DE), Schnapp; Andreas (Biberach, DE), Bouyssou; Thierry (Mietingen, DE), Buettner; Frank (Ummendorf, DE), Heine; Claudia (Biberach, DE), Lustenberger; Philipp (Warthausen, DE), Hoenke; Christoph (Ingelheim, DE), Rudolf; Klaus (Warthausen, DE)
Assignee:	Boehringer Ingelheim Pharma GmbH & Co., KG (Ingelheim, DE)
Application Number:	11/677,112
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 7,727,984

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide	SPRAY, METERED;INHALATION	206756-001	May 21, 2015		RX	Yes	Yes				Y
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014		RX	Yes	Yes				Y

Foreign Priority and PCT Information for Patent: 7,727,984

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	102 53 282	Nov 15, 2002

Non-Orange Book US Patents Family Members for Patent 7,727,984

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,044,046	Medicaments for the treatment of chronic obstructive pulmonary disease
7,056,916	Medicaments for the treatment of chronic obstructive pulmonary disease
7,786,111	Medicaments for the treatment of chronic obstructive pulmonary disease

International Family Members for US Patent 7,727,984

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Slovenia	1562603
New Zealand	540661
Norway	334314
Norway	20052883